Pinostrobin and its derivatives as novel anti-breast cancer agents against human oestrogen receptor alpha: In silico studies of ADMET, docking, and molecular dynamics
DOI:
https://doi.org/10.46542/pe.2024.243.5156Keywords:
Breast cancer, Docking, Molecular dynamic, Oestrogen receptor alpha, PinostrobinAbstract
Background: Breast cancer is the main cause of cancer death among women. The issue is more complex due to the side effects and resistance of the currently used breast cancer drugs. Pinostrobin, a compound found in Boesenbergia pandurata, has anticancer activity. Modifying the structure of pinostrobin can improve drug bioavailability, reduce toxicity, and work more selectively.
Objective: This study aimed to predict the potentials of pinostrobin and its derivatives as anti-breast cancer agents against human oestrogen receptors by an in silico approach.
Methods: The pkCSM was utilised to predict the ADMET characteristics. The interaction of ligands with the binding site of the human oestrogen receptor alpha with PDB ID 3ERT was used for molecular docking using MOE, and AMBER was then used for molecular dynamic simulation.
Results: Pinostrobin pentanoate had good pharmacokinetic properties and was neither mutagenic nor hepatotoxic. Based on molecular docking, it was more potent compared to pinostrobin, with binding free energy values of -7.849 kcal/mol. Furthermore, in the interaction stability evaluation using 100 ns molecular dynamic simulation by the MM-GBSA calculation method, pinostrobin pentanoate had a stable interaction with a total bond energy value of -9.943 kcal/mol.
Conclusion: Pinostrobin pentanoate has the potential as an anti-breast cancer alternative through the human oestrogen receptor alpha.
References
Agustin, S. L., Widiandani, T., Hardjono, S., & Purwanto, B. T. (2022). QSAR of Acyl pinostrobin derivatives as Anti-breast cancer against HER-2 receptor and their ADMET properties based on in silico Study. Research Journal of Pharmacy and Technology, 15(10), 4641‒4648. https://doi.org/10.52711/0974-360X.2022.00779
Bandyopadhyay, A., Wang, L., Agyin, J., Tang, Y., Lin, S., & Yeh, I. (2010). Doxorubicin in combination with a small TGFβ inhibitor: A potential novel therapy for metastatic breast cancer in mouse models. PLoS ONE, 5(4), e10365. https://doi.org/10.1371%2Fjournal.pone.0010365
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394–424. https://doi.org/10.3322/caac.21492
Childs, A. C., Phaneuf, S. L., Dirks, A. J., Phillips, T., & Leeuwenburgh, C. (2002). Doxorubicin treatment in vivo causes cytochrome c release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2: Bax ratio 1. Cancer Research, 62(16), 4592‒4598.
GLOBOCAN. (2020). Cancer. Global Cancer Observatory. https://gco.iarc.fr/
Ho, B. K., & Brasseur, R. (2005) The Ramachandran plots of glycine and pre-proline. BMC Struct Biol, 5(1), 14. https://doi.org/10.1186/1472-6807-5-14
Ikegawa, T., Ohtani, H., Koyabu, N., Juichi, M., Iwase, Y., Ito, C., Furukawa, H., Naito, M., Tsuruo, T., & Sawada, Y. (2002). Inhibition of P-glycoprotein by flavonoid derivatives in adriamycin-resistant human myelogenous leukemia (K562/ADM) cells. Cancer Letters, 177(1), 89‒93. https://doi.org/10.1016/S0304-3835(01)00761-3
Kumar, S., Sharma, P. P., Shankar, U., Kumar, D., Joshi, S. K., Pena, L., Durvasula, R., Kumar, A., Kempaiah, P., Poonam, & Rathi, B. (2020). Discovery of new hydroxyethylamine analogs against 3CLproProtein target of SARS-CoV-2: Molecular docking, molecular dynamics simulation, and structure-activity relationship studies. J Chem Inf Model 60(12), 5754–5770. https://doi.org/10.1021/acs.jcim.0c00326
Liu, Y., Ma H., & Yao J. (2020). Erα, a key target for cancer therapy: A review. Onco Targets Ther, 2020(13) 2183‒2191. https://doi.org/10.2147/OTT.S236532
Lovitt, C. J., Shelper, T. B., & Avery, V. M. (2018). Doxorubicin resistance in breast cancer cells is mediated by extracellular matrix proteins. BMC Cancer, 18(1), 41. https://doi.org/10.1186/s12885-017-3953-6
Pires, D. E. V., Blundell, T. L., & Ascher, D. B. (2015). PkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. Journal of Medical Chemical 58(9): 4066–4072. https://doi.org/10.1021/acs.jmedchem.5b00104
Praditapuspa, E. N., Siswandono, & Widiandani, T. (2021). In silico analysis of pinostrobin derivatives from Boesenbergia pandurata on ErbB4 kinase target and QSPR linear models to predict drug clearance for searching anti-breast cancer drug candidates. Pharmacognosy Journal, 13(5), 1143–1149. https://doi.org/10.5530/pj.2021.13.147
Pratama, M. R. F., Praditapuspa, E. N., Kesuma, D., Poerwono, H., Widiandani, T., & Siswodihardjo, S. (2022). Boesenbergia Pandurata as an Anti-Breast Cancer Agent: Molecular Docking and ADMET Study. Letters in Drug Design and Discovery, 19 (7): 606‒626. https://doi.org/10.2174/1570180819666211220111245
Purwantiningsih, Jannah, N., & Rahayu, D. U. C. (2020). Two flavanones from finger-root (Curcuma rotunda) and its antibacterial activities. Rasayan Journal of Chemistry, 13(1), 322–326. https://doi.org/10.31788/RJC.2020.1315484
Renadi, S., Pratita, A. T. K., Mardianingrum, R., & Ruswanto, R. (2023). The potency of alkaloid derivatives as anti-breast cancer candidates: in silico study. Jurnal Kimia Valensi, 9(1), 89‒108. https://doi.org/10.15408/jkv.v9i1.31481
Ruswanto, Mardianingrum, R., Lestari, T., Nofianti, T., Tuslinah, L., & Nurmalik, D. (2018). In silico study of the active compounds in bitter melon (Momordica charantia L) as antidiabetic medication. Pharmaciana, 8(2), 194. https://doi.org/10.12928/pharmaciana.v8i2.8993
Ruswanto, Mardianingrum, R., Siswandono., & Kesuma, D. (2020). Reverse docking, molecular docking, absorption, distribution, and toxicity prediction of artemisinin as an antidiabetic candidate. Molekul, 15(2), 88‒96. https://doi.org/10.20884/1.jm.2020.15.2.579
Siswandono, Widyowati, R., Suryadi, A., Widiandani, T., & Prismawan, D. (2020). Molecular modeling, synthesis, and qsar of 5-o-acylpinostrobin derivatives as promising analgesic agent. Rasayan Journal of Chemistry, 13(4), 2559–2568. https://doi.org/10.31788/RJC.2020.1345749
Siswandono. (2014). Drug development, First Edition. Airlangga University Press.
Widiana I, K., & Irawan, H. (2020). Clinical and subtypes of breast cancer in Indonesisa. Asian Pacific Journal of Cancer Care, 5(4), 281‒285. https://doi.org/10.31557/APJCC.2020.5.4.281
Widiandani, T., Tandian, T., Zufar, B. D., Suryadi, A., Purwanto, B. T., Hardjono, S., & Siswandono, S. (2023). In vitro study of pinostrobin propionate and pinostrobin butyrate: Cytotoxic activity against breast cancer cell T47D and its selectivity index. Journal of Public Health in Africa, 14(1), 2516. https://doi.org/10.4081/jphia.2023.2516
